- Global Pharma News & Resources

AC Immune to Present at the SVB Securities Global Biopharma Conference

AC Immune to Present at the SVB Securities Global Biopharma Conference

Lausanne, Switzerland, February 2, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in a fireside chat and one-on-one investor meetings during the SVB Securities Global Biopharma Conference, which is taking place virtually from February 14 – 16, 2023.

During the fireside chat, AC Immune’s CEO Dr. Andrea Pfeifer will provide an overview of the company’s precision medicine approach and pipeline, which includes 16 therapeutic and diagnostic programs collectively designed to shift the neurodegenerative disease treatment paradigm towards earlier diagnosis and disease prevention. Dr. Pfeifer will also discuss the company’s wholly-owned anti-amyloid beta vaccine, ACI-24.060, which recently showed positive initial interim safety and immunogenicity in patients with Alzheimer’s disease in the Phase 1b/2 ABATE trial.

The fireside chat will take place on February 14, 2023, at 8:40 AM ET / 2:40 PM CET. A webcast of the fireside chat will be available on the Events Page of AC Immune’s website. Following the fireside chat, a replay will be archived in the same location.

About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features ten therapeutic and three diagnostic candidates, five of which are currently in Phase 2 clinical trials and one of which is in Phase 3. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and others, resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.

SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.

The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.

Editor Details

Last Updated: 03-Feb-2023